

	Page
Scoville, Barrett, M.D., of Washington, D.C.-----	14961
Yaffe, Sumner J., M.D., professor of clinical pharmacology and pediatrics, University of Pennsylvania and director, Division of Clinical Pharma- cology, Children's Hospital, Philadelphia, Pa.-----	14967
Yake, Reverend Reginald, executive director, Teen Challenge Training Cen- ter, Rehrersburg, Pa.-----	14971

MATERIAL SUPPLIED FOR THE RECORD BY SENATOR NELSON

ACTIONS BY THE FOOD AND DRUG ADMINISTRATION AND DRUG ENFORCEMENT AGENCY SINCE TERMINATION OF HEARINGS

Letter dated Feb. 16, 1977, to Senator Gaylord Nelson, chairman, Senate Small Business Committee, from J. Richard Crout, M.D., Director, Bureau of Drugs, FDA-----	14975
Letter dated Jan. 28, 1977, to Benjamin Gordon, staff economist, Senate Small Business Committee, from J. Richard Crout, M.D., Director, Bureau of Drugs, FDA-----	14977
Letter dated Dec. 20, 1976, to Sherwin Gardner, Acting Commissioner, Food and Drug Administration, from Peter B. Bensinger, Administrator, Drug Enforcement Administration, Department of Justice, with accom- panying enclosures-----	14979

ANTI-OBESITY DRUGS—GENERAL

Memorandum dated Feb. 5, 1964, to Ralph C. Smith, M.D., Acting Medical Director, from Robert O. Knox, M.D., Medical Officer, FDA-----	15052
Memorandum dated July 28, 1967, to Merle L. Gibson, M.D., Acting Director, Division of Neuropharmacological Drugs, from Robert O. Knox, M.D., Medical Officer, FDA-----	15052
Memorandum dated May 19, 1969, to Merle L. Gibson, M.D., Director, Division of Neuropharmacological Drugs, from Robert O. Knox, M.D., Medical Officer, FDA-----	15052
Memorandum dated Nov. 18, 1969, to John Jennings, M.D., Acting Director, Bureau of Medicine from Robert O. Knox, M.D., Medical Officer, FDA-----	15054
Memorandum dated Feb. 17, 1970, to John Jennings, M.D., Acting Director, Bureau of Medicine, from Robert O. Knox, M.D., Medical Officer, FDA-----	15054
Memorandum dated Apr. 8, 1970, to John Jennings, M.D., Acting Direc- tor, Bureau of Drugs, from Robert O. Knox, M.D., Medical Officer, FDA-----	15056
Memorandum dated Apr. 9, 1971, to Barrett Scoville, M.D., Deputy Director, from Robert O. Knox, M.D., Medical Officer, FDA-----	15057
Memorandum dated Apr. 12, 1971, to Henry E. Simmons, M.D., Director, Bureau of Drugs, from Barrett Scoville, M.D., Deputy Director, FDA-----	15058
Memorandum dated Apr. 19, 1971, to Dr. Marion Finkel, Deputy Direc- tor, Bureau of Drugs, from Leszek Ochota, M.D., FDA-----	15059
Memorandum dated Sept. 22, 1971, to the Commissioner, from Henry E. Simmons, M.D., Director, Bureau of Drugs, FDA-----	15059
Paper, "The FDA Review of Anorectic Drugs: Background, Current Status, and Problem Areas," presented by Barrett Scoville, M.D., Deputy Director, and Elmer A. Gardner, M.D., Director, Division of Neuropharmacological Drug Products, FDA, June 12, 1972-----	15060
Final report to the Director, Bureau of Drugs, FDA, by Thaddeus E. Prout, M.D., Chairman, Consultants on Anorectic Drugs-----	15064
Memorandum dated Oct. 6, 1972, to the Commissioner, from Henry E. Simmons, M.D., Director, Bureau of Drugs, FDA-----	15066
Letter dated Mar. 26, 1973, to Delco Chemical Co., Inc., from Sherwin Gardner, Acting Commissioner, FDA, and John E. Ingersoll, Director, Bureau of Narcotics and Dangerous Drugs-----	15068
Letter dated Sept. 28, 1974, to Dr. Alexander M. Schmidt, Commissioner, FDA, from Robert O. Knox, M.D., Medical Officer, FDA-----	15069
Memorandum dated July 9, 1976, to Ed Melton, OLS, from Bill Crabbs, HFD-120, FDA-----	15076
Memorandum undated, to the Director, Bureau of Drugs, from J. Richard Crout, M.D., Acting Director, Office of Scientific Evaluation, FDA-----	15070